Lenvatinib is a potential molecular target of KIT, PDGFR-α, and FGFR, and it shows antitumor activity in HCC (hepatocellular carcinoma) by targeting FGF/FGFR signaling; however, further investigation into its anti-FGFR activity is required [43]. This evidence concerns the gene PDGFRA and hepatocellular carcinoma.